Maintenance Notice (3:15 - 7:30 AM February 22, 2025 UTC): This website is scheduled to be unavailable due to maintenance. We appreciate your patience and understanding.
Notice of Discontinuing the Use of Password-Protected Compressed Files | Product Document Searching Made Easy by 2D Code! | TCI Life Science News February 2025 | [Product Highlights] Chemiluminescent Reagents for... | Various analytical charts can be searched on each product detail page and Product Document Search (The kinds of analytical charts differ by product)
Maximum quantity allowed is 999
请选择数量
CAS RN: 29094-61-9 | 產品號碼: G0369
| 產品號碼 | G0369 |
| 純度/分析方法 | >98.0%(T)(HPLC) |
| 分子式 / 分子量 | C__2__1H__2__7N__5O__4S = 445.54 |
| 外觀與形狀（20°C） | Solid |
| 儲存條件 | Room Temperature (Recommended in a cool and dark place, <15°C) |
| 包裝和容器 | 1G-Glass Bottle with Plastic Insert （閲覽圖片） |
| CAS RN | 29094-61-9 |
| Reaxys-RN | 903495 |
| PubChem Substance ID | 125307849 |
| SDBS (AIST Spectral DB) | 52971 |
| Merck Index(14) | 4442 |
| MDL編號 | MFCD00072159 |
產品規格
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Neutralization titration) | min. 98.0 % |
性質
| 熔點 | 206 °C |
GHS
相關法規
| RTECS # | YS7640000 |
運輸資料
| HS編碼* | 2935.90-000 |
Application
Glipizide: A Sulfonylurea ATP-Dependent K+ Channel Antagonist
Glipizide belongs to sulfonylurea antidiabetics which increase the release of insulin from pancreatic B-cells. Sulfonylurea antidiabetics inhibit ATP-gated K+ channels and thereby cause depolarization of the B-cell membrane. The depolarization leads to activation of voltage-dependent Ca channels and Ca2+ influx into the B-cell, and eventually increases insulin release. In addition, glipizide is characterized by poor solubility in water. Therefore, it has been studied to improve the solubility and bioavailability of drug. (The product is for research purpose only. (The product is for research purpose only.)
References
- Glipizide: a review of its pharmacological properties and therapeutic use
- The receptor for antidiabetic sulfonylureas controls the activity of the ATP-modulated K+ channel in insulin-secreting cells
- Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: A model for type 2 diabetes and pharmacological screening
- Enhancement of the dissolution rate and bioavailability of glipizide through cyclodextrin inclusion complex
- Development of a controlled release low dose class II drug-Glipizide
- The development and validation of liquid chromatography method for the simultaneous determination of metformin and glipizide, gliclazide, glibenclamide, or glimperide in plasma
- Simultaneous estimation of six anti-diabetic drugs-glibenclamide, gliclazide, glipizide, pioglitazone, repaglinide and rosiglitazone: development of a novel HPLC method for use in the analysis of pharmaceutical formulations and its application to human plasma assay
考研文獻
文章/手冊
TCIMail
產品文件 （部分產品的分析圖譜無法提供，敬請諒解。）
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助，請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注：該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉，您搜索的分析圖譜無法提供。